Accessibility Menu
 
Bolt Biotherapeutics logo

Bolt Biotherapeutics

(NASDAQ) BOLT

Current Price$4.71
Market Cap$9.19M
Since IPO (2021)-99%
5 Year-99%
1 Year-25%
1 Month-3%

Bolt Biotherapeutics Financials at a Glance

Market Cap

$9.19M

Revenue (TTM)

$6.50M

Net Income (TTM)

$29.58M

EPS (TTM)

$-16.34

P/E Ratio

-0.29

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$4.71

Volume

2

Open

$4.81

Previous Close

$4.78

Daily Range

$4.65 - $4.81

52-Week Range

$3.91 - $9.25

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bolt Biotherapeutics

Industry

Biotechnology

Employees

23

CEO

William P. Quinn, MBA

Headquarters

Redwood City, CA 94063, US

BOLT Financials

Key Financial Metrics (TTM)

Gross Margin

97%

Operating Margin

-5%

Net Income Margin

-5%

Return on Equity

-89%

Return on Capital

-74%

Return on Assets

-62%

Earnings Yield

-3.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.19M

Shares Outstanding

1.92M

Volume

2

Avg. Volume

24.47K

Financials (TTM)

Gross Profit

$6.20M

Operating Income

$34.63M

EBITDA

$33.14M

Operating Cash Flow

$39.85M

Capital Expenditure

$72.00K

Free Cash Flow

$39.92M

Cash & ST Invst.

$27.50M

Total Debt

$22.96M

Bolt Biotherapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$26.00K

-97.9%

Gross Profit

$177.00K

-114.5%

Gross Margin

-6.81%

N/A

Market Cap

$9.19M

N/A

Market Cap/Employee

$176.64K

N/A

Employees

52

N/A

Net Income

$7.24M

+34.4%

EBITDA

$7.40M

+36.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$584.00K

-95.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$19.35M

-13.3%

Short Term Debt

$2.96M

+23.2%

Return on Assets

-61.59%

N/A

Return on Invested Capital

-74.03%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$8.02M

+40.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLRBCellectar Biosciences, Inc.
$3.09-3.44%
INABIN8bio, Inc.
$1.49-6.29%
IMNNImunon, Inc.
$2.49-2.35%
RNAZTransCode Therapeutics, Inc.
$6.60-2.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.06-0.10%
INTCIntel
$108.77-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.98+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$75.34-0.05%

Questions About BOLT

What is the current price of Bolt Biotherapeutics?

Bolt Biotherapeutics is trading at $4.78 per share.

What is the 52-week range for Bolt Biotherapeutics?

Over the past 52 weeks, Bolt Biotherapeutics has traded between $3.91 and $9.25.

How much debt does Bolt Biotherapeutics have?

As of the most recent reporting period, Bolt Biotherapeutics reported total debt of $22.31M.

How much cash does Bolt Biotherapeutics have on hand?

Bolt Biotherapeutics reported $11.81M in cash and cash equivalents in its most recent financial results.

What is Bolt Biotherapeutics’s dividend yield?

Bolt Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.